30 Day Trial

Xtant Medical Announces Preliminary 3Q15 Revenue


Xtant Medical announced preliminary 3Q15 revenue in the range of US $20.7MM to $20.9MM, growth of +5.5% to 6.5% vs. 3Q14. Assuming the upper end of revenue, 3Q15 includes Bacterin sales of $9.9MM, X-spine non-OEM sales of $10.3MM and X-spine OEM sales of $0.7MM. 

Bacterin announced its intent to purchase outstanding common stock of X-spine Systems in early 3Q15, creating Xtant. 

Source: Xtant Medical, Inc.